Shares of ImmuPharma plc (LON:IMM – Get Free Report) traded down 8.3% during trading on Wednesday . The company traded as low as GBX 4.11 ($0.05) and last traded at GBX 4.59 ($0.06). 7,864,863 shares traded hands during trading, a decline of 65% from the average session volume of 22,321,723 shares. The stock had previously closed at GBX 5 ($0.06).
ImmuPharma Stock Performance
The business’s 50 day moving average price is GBX 2.46 and its two-hundred day moving average price is GBX 1.95. The company has a market capitalization of £20.11 million, a price-to-earnings ratio of -483.00 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- What Are Dividend Champions? How to Invest in the Champions
- IBM’s AI Bet Pays Off—What’s Next for Investors?
- How to Short Nasdaq: An Easy-to-Follow Guide
- 3 Reasons to Treat AMD’s Drop as an Entry Opportunity
- Breakout Stocks: What They Are and How to Identify Them
- Qualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
